ASH Abstracts 2021, Partial List

John Mascarenhas, MD
Treatment of Myelofibrosis Patients with the TGF-β 1/3 Inhibitor AVID200 (MPN-RC 118) Induces a Profound Effect on Platelet Production
Oral
Saturday, December 11, 2021, 12:45 pm

Yelena Ginzburg, MD
Rusfertide (PTG-300) Induction Therapy Rapidly Achieves Hematocrit Control in Polycythemia Vera Patients without the Need for Therapeutic Phlebotomy
Oral
Sunday, December 12, 2021, 10:45 am

Douglas Tremblay, MD
European Leukemianet (ELN) Response Predicts Disease Progression but Not Thrombosis or Death in Polycythemia Vera (PV): An Analysis of a Multicenter Database
Oral
Saturday, December 11, 2021, 3:15 pm

Santiago Thibaud, MD
Pathogenic Germline Variants in Multiple Myeloma
Oral
Sunday, December 12, 2021, 10 am
ASH Abstract Achievement Award

David Melnekoff, MS
Single-Cell Profiling Reveals Contribution of Tumor Extrinsic and Intrinsic Factors to BCMA-Targeted CAR-T Cell Efficacy in Multiple Myeloma
Oral
Saturday, December 11, 2021, 4:15 pm

Emily Gallagher, MD, PhD
Genomic and Systemic Metabolism Differences Associated with Racial Disparities in Multiple Myeloma
Poster
Saturday, December 11, 2021, 5:30 - 7:30 pm

Paula Restrepo, BA
Transcriptomic Correlates of Response to Selinexor in Multiple Myeloma Reveal a Predictive Signature
Oral
Sunday, December 12, 2021, Noon

Oliver Van Oekelen, MD, MSc
Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T
Poster
Sunday, December 12, 2021, 6 - 8 pm

Oliver Van Oekelen, MD, MSc
Large-Scale Mass Cytometry Reveals Significant Activation of Innate and Adaptive Immunity in Bone Marrow Tumor Microenvironment of Iberdomide-Treated Myeloma Patients
Oral
Monday, December 13, 2021, 3:30 pm

Tarek Mouhieddine, MD
Clinical Outcomes of Relapsed/Refractory Multiple Myeloma Patients Following Treatment with Bispecific Antibodies (BiAbs)
Oral
Monday, December 13, 2021, 5:30 pm

Oliver Van Oekelen, MD, MSc
Suboptimal Humoral and Cellular Immune Response to SARS-CoV-2 RNA Vaccination in Myeloma Patients Is Associated with Anti-CD38 and BCMA-Targeted Treatment
Oral
Monday, December 13, 2021, 5:45 pm

Ajai Chari, MD
Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma
Oral
Saturday, December 11, 2021, 1 pm

Marina Kremyanskaya, MD, PhD
Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis – Update of Clinical and Translational Data from the Ongoing Manifest Trial
Oral
Saturday, December 11, 2021, 12:30 pm

Bridget Marcellino, MD, PhD, and Alan Shih, MD, PhD
Development of an MDM2 Degrader for Treatment of Acute Leukemias
Poster
Saturday, December 11, 2021, 5:30 - 7:30 pm

Tarek H. Mouhieddine, MD
Clonal Hematopoiesis Prevalence Increases throughout Treatment of Newly Diagnosed Multiple Myeloma Patients
Poster
Saturday, December 11, 2021, 5:30 - 7:30 pm

Shivani Handa, MBBS
Obstetrical and Peri-Operative Management of Patients with Factor XI Deficiency – a Retrospective Observational Study
Oral
Sunday, December 12, 2021, 5 pm

Ines Stefania Mancia, NP
Characterization and Management of Oral and Dermatological Toxicities in Patients Receiving the CD3 X GPRC5D Bispecific Antibody Talquetamab (JNJ-64407564) for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Poster
Saturday, December 11, 2021, 5:30 - 7:30 pm

Joshua Richter, MD
Subgroup Analysis: Efficacy and Safety of Panobinostat in Combination with SC Bortezomib and Oral Dexamethasone in Multiple Myeloma Patients with Lenalidomide-Refractory Disease
Poster
Monday, December13, 2021, 6 - 8 pm

Joshua Richter, MD
Real-World Multiple Myeloma Treatment Patterns By Patient Characteristics and Outcomes in the United States
Poster
Monday, December 13, 2021, 6 - 8 pm

Ronald Hoffman, MD
Rusfertide (PTG-300) Controls Hematocrit Levels and Essentially Eliminates Phlebotomy Requirement in Polycythemia Vera Patients
Oral
Sunday, December 12, 2021, 10:15 am

Andrew Srisuwananukorn, MD
Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics
Poster
Sunday, December 12, 2021, 6 - 8 pm

Xiaoli Wang, MD, PhD
Navtemadlin (KRT-232), a Small Molecule MDM2 Inhibitor, Is More Effective Than Decitabine Against Myeloproliferative Neoplasm-Blast Phase in a Patient-Derived Xenograft Model
Poster
Monday, December 13, 2021, 6 - 8 pm